Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
DXR 
Daxor Corporation (DXR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/11/2025: DXR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -31.73% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.07M USD | Price to earnings Ratio - | 1Y Target Price 23.5 |
Price to earnings Ratio - | 1Y Target Price 23.5 | ||
Volume (30-day avg) 6910 | Beta -0.53 | 52 Weeks Range 6.55 - 10.00 | Updated Date 03/31/2025 |
52 Weeks Range 6.55 - 10.00 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 448.01% | Operating Margin (TTM) -2368.66% |
Management Effectiveness
Return on Assets (TTM) -2.51% | Return on Equity (TTM) 1.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 42930072 | Price to Sales(TTM) 334.68 |
Enterprise Value 42930072 | Price to Sales(TTM) 334.68 | ||
Enterprise Value to Revenue 18.91 | Enterprise Value to EBITDA - | Shares Outstanding 4934180 | Shares Floating 2114544 |
Shares Outstanding 4934180 | Shares Floating 2114544 | ||
Percent Insiders 57 | Percent Institutions 2.13 |
Analyst Ratings
Rating 4.5 | Target Price 23.38 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Daxor Corporation
Company Overview
History and Background
Daxor Corporation, founded in 1971, is a biotechnology company focused on blood volume measurement technology. It developed and commercialized the BVA-100 blood volume analyzer and related products.
Core Business Areas
- Blood Volume Analysis (BVA): Develops, manufactures, and markets the BVA-100, a diagnostic tool used to precisely measure blood volume. Also manufactures related supplies and offers services related to BVA testing.
Leadership and Structure
Daxor is led by a board of directors and executive management team. The company operates with a structure focused on research, development, manufacturing, and sales of its BVA technology.
Top Products and Market Share
Key Offerings
- BVA-100 (Blood Volume Analyzer): Daxor's flagship product, the BVA-100, is a diagnostic device that accurately measures a patient's blood volume. Market share data is not publicly available but given the niche market the Company is a market leader. Competitors are traditional methods of assessing fluid status, which are inaccurate.
Market Dynamics
Industry Overview
The industry involves diagnostic tools and services used to assess and manage patient fluid status. The clinical need for accurate blood volume assessment exists in various medical fields, including cardiology, nephrology, and critical care.
Positioning
Daxor is positioned as a provider of precise blood volume measurement technology, offering a more accurate alternative to traditional methods. Their BVA-100 is marketed as a tool for improved patient management and clinical outcomes.
Total Addressable Market (TAM)
The TAM for blood volume analysis is estimated at several billion dollars, encompassing hospital systems, research institutions, and diagnostic labs. Daxor's current market share is a small percentage of this, indicating significant growth potential.
Upturn SWOT Analysis
Strengths
- Proprietary BVA technology
- First FDA approved BVA device
- Established presence in specialized medical fields
- High degree of accuracy and reliability
Weaknesses
- Limited financial resources compared to larger diagnostic companies
- Reliance on a single core product
- Market awareness is still developing
- Relatively small sales and marketing team
Opportunities
- Expanding applications of BVA technology in new medical specialties
- Partnerships with hospitals and research institutions
- Increased awareness of the importance of accurate blood volume assessment
- Potential for international market expansion
Threats
- Emergence of competing blood volume measurement technologies
- Changes in healthcare regulations and reimbursement policies
- Economic downturn impacting hospital budgets
- Slow adoption rates of new diagnostic technologies
Competitors and Market Share
Key Competitors
- ICU Medical (ICUI)
- Fresenius Medical Care (FMS)
- Baxter International (BAX)
Competitive Landscape
Daxor's advantage lies in its proprietary BVA technology, offering a more accurate measurement of blood volume compared to traditional methods. However, it faces competition from larger companies with broader product portfolios and greater financial resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Daxor's historical growth has been moderate, driven by the adoption of its BVA technology in specific medical fields.
Future Projections: Future growth projections depend on the company's ability to expand its market reach, develop new applications for its technology, and secure partnerships. Analyst estimates are not readily available.
Recent Initiatives: Recent initiatives include efforts to promote BVA-100 to hospitals and research institutions and to develop new applications for the technology.
Summary
Daxor Corporation is a biotechnology company with proprietary blood volume analysis technology. Its strength lies in the accuracy of its BVA-100, but it faces challenges due to limited resources and market awareness. The company's future growth depends on expanding its market reach and forging strategic partnerships. They need to be aware of competing technologies as well as the adoption rate in the medical field.
Similar Companies
- ICUI
- BAX
- FMS
Sources and Disclaimers
Data Sources:
- Daxor Corporation's website
- SEC filings
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Daxor Corporation
Exchange NASDAQ | Headquaters Oak Ridge, TN, United States | ||
IPO Launch date 1992-03-17 | Chairman, President & CEO Mr. Michael Richard Feldschuh | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees - | Website https://www.daxor.com |
Full time employees - | Website https://www.daxor.com | ||
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.